David Wraith has worked in the field of T cell biology and the role of T lymphocytes in protection from infection and in autoimmunity since 1981. 

Since 1995 his laboratory in Bristol has focused on the mechanism of antigen-specific immunotherapy. His work provided the essential rules governing the design of therapeutic peptides and led to the establishment of a University of Bristol spinout company, Apitope NV. 

The company has designed peptides for treatment of various autoimmune diseases and has successfully completed phase 2 trials in relapsing multiple sclerosis. David’s research laboratory is currently defining the differentiation pathway of antigen induced Treg cells and the mechanism by which these cells suppress disease. The aim of this approach is to improve the efficacy of peptide therapy for treating allergic and autoimmune diseases in humans.